Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

PURPOSE: Dinaciclib inhibits cyclin-dependent kinases 1, 2, 5, and 9 with a better therapeutic index than flavopiridol in preclinical studies. This study assessed the activity of dinaciclib in acute leukemia both in the clinic and in vitro. METHODS: Adults with relapsed/refractory acute myeloid leuk...

Descripción completa

Detalles Bibliográficos
Autores principales: Gojo, Ivana, Sadowska, Mariola, Walker, Alison, Feldman, Eric J., Iyer, Swaminathan Padmanabhan, Baer, Maria R., Sausville, Edward A., Lapidus, Rena G., Zhang, Da, Zhu, Yali, Jou, Ying-Ming, Poon, Jennifer, Small, Karen, Bannerji, Rajat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784060/
https://www.ncbi.nlm.nih.gov/pubmed/23949430
http://dx.doi.org/10.1007/s00280-013-2249-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784060/
https://www.ncbi.nlm.nih.gov/pubmed/23949430
http://dx.doi.org/10.1007/s00280-013-2249-z

Ejemplares similares